Literature DB >> 29260486

An Evidence-Based, Community-Engaged Approach to Develop an Interactive Deliberation Tool for Pediatric Neuromuscular Trials.

Rebecca R Moultrie1, Megan A Lewis2, Ryan S Paquin2, Ann Lucas3, Jill Jarecki4, Holly L Peay2,3.   

Abstract

Duchenne/Becker muscular dystrophy (DBMD) and spinal muscular atrophy (SMA) are rare neuromuscular disorders that present challenges to therapeutic and clinical trial decision making. We developed an interactive, evidence-based online tool designed to encourage thoughtful deliberation of the pros and cons of trial participation and to inform meaningful discussions with healthcare providers. Prior research demonstrates the importance of tool availability at the time each family is considering trial participation, which may be prior to the informed consent process. The tool is intended to be easily modified to other pediatric disease communities. Tool development was informed by prior qualitative research, literature reviews, and stakeholder input. Specific items were derived based on an online exploratory questionnaire of parents whose children participated in a trial for DBMD or SMA to understand motivations for participation. Parent participants in the exploratory survey reported strong impact of altruistic and individual benefit motivations and placed much greater emphasis on anticipated trial benefits than on harms when making participation decisions. We used this data to develop the evidence-based deliberation tool using a community-engaged approach. We initially targeted the tool for DBMD while using SMA survey data to evaluate ease of transition to that population. We conducted two iterative sets of activities to inform development and refinement of the tool: (1) community engagement of key stakeholders and (2) user experience testing. These activities suggest that the tool may increase deliberation and the weighing of benefits and harms. Ongoing evaluation will determine the acceptability and efficacy of this online intervention.

Entities:  

Keywords:  Clinical trial; Decision aid; Duchenne muscular dystrophy; Informed consent; Parental decision making; Spinal muscular atrophy

Mesh:

Year:  2017        PMID: 29260486     DOI: 10.1007/s10897-017-0190-8

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  23 in total

1.  Spinal muscular atrophy approval boosts antisense drugs.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2017-02-08       Impact factor: 54.908

2.  Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne/Becker muscular dystrophy.

Authors:  Holly L Peay; Aad Tibben; Tyler Fisher; Ethan Brenna; Barbara B Biesecker
Journal:  Clin Trials       Date:  2013-12-04       Impact factor: 2.486

3.  Randomized trial examining the effect of two prostate cancer screening educational interventions on patient knowledge, preferences, and behaviors.

Authors:  Melissa R Partin; David Nelson; David Radosevich; Sean Nugent; Ann B Flood; Nancy Dillon; Jeremy Holtzman; Michele Haas; Timothy J Wilt
Journal:  J Gen Intern Med       Date:  2004-08       Impact factor: 5.128

4.  Review of Spinal Muscular Atrophy (SMA) for Prenatal and Pediatric Genetic Counselors.

Authors:  Amanda Carré; Candice Empey
Journal:  J Genet Couns       Date:  2015-08-08       Impact factor: 2.537

5.  Toward the 'tipping point': decision aids and informed patient choice.

Authors:  Annette M O'Connor; John E Wennberg; France Legare; Hilary A Llewellyn-Thomas; Benjamin W Moulton; Karen R Sepucha; Andrea G Sodano; Jaime S King
Journal:  Health Aff (Millwood)       Date:  2007 May-Jun       Impact factor: 6.301

Review 6.  Duchenne and Becker muscular dystrophies.

Authors:  Kevin M Flanigan
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

7.  Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy.

Authors:  Jane T Seto; Niclas E Bengtsson; Jeffrey S Chamberlain
Journal:  Curr Pediatr Rep       Date:  2014-06-01

8.  "Watching time tick by…": Decision making for Duchenne muscular dystrophy trials.

Authors:  Holly L Peay; Hadar Scharff; Aad Tibben; Benjamin Wilfond; Janice Bowie; Joanna Johnson; Kanneboyina Nagaraju; Diana Escolar; Jonathan Piacentino; Barbara B Biesecker
Journal:  Contemp Clin Trials       Date:  2015-11-09       Impact factor: 2.226

9.  Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.

Authors:  Claudia A Chiriboga; Kathryn J Swoboda; Basil T Darras; Susan T Iannaccone; Jacqueline Montes; Darryl C De Vivo; Daniel A Norris; C Frank Bennett; Kathie M Bishop
Journal:  Neurology       Date:  2016-02-10       Impact factor: 9.910

10.  Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.

Authors:  Manon Haché; Kathryn J Swoboda; Navil Sethna; Alan Farrow-Gillespie; Alexander Khandji; Shuting Xia; Kathie M Bishop
Journal:  J Child Neurol       Date:  2016-01-27       Impact factor: 1.987

View more
  4 in total

1.  Introduction to the "Technology in Practice" Special Issue.

Authors:  Vickie Venne; Megan Doerr
Journal:  J Genet Couns       Date:  2018-03-01       Impact factor: 2.537

2.  "Be an ambassador for change that you would like to see": a call to action to all stakeholders for co-creation in healthcare and medical research to improve quality of life of people with a neuromuscular disease.

Authors:  Anna Ambrosini; Ros Quinlivan; Valeria A Sansone; Ingeborg Meijer; Guus Schrijvers; Aad Tibben; George Padberg; Maarten de Wit; Ellen Sterrenburg; Alexandre Mejat; Alexandra Breukel; Michal Rataj; Hanns Lochmüller; Raffaella Willmann
Journal:  Orphanet J Rare Dis       Date:  2019-06-07       Impact factor: 4.123

3.  Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents.

Authors:  Holly Landrum Peay; Ryan Fischer; Janice P Tzeng; Sharon E Hesterlee; Carl Morris; Amy Strong Martin; Colin Rensch; Edward Smith; Valeria Ricotti; Katherine Beaverson; Hannah Wand; Carol Mansfield
Journal:  PLoS One       Date:  2019-05-01       Impact factor: 3.240

4.  Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients.

Authors:  Ryan S Paquin; Ryan Fischer; Carol Mansfield; Brennan Mange; Katherine Beaverson; Annie Ganot; Amy Strong Martin; Carl Morris; Colin Rensch; Valeria Ricotti; Leo J Russo; Alesia Sadosky; Edward C Smith; Holly L Peay
Journal:  Orphanet J Rare Dis       Date:  2019-05-09       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.